98%
921
2 minutes
20
The typical way in which lead optimisation (LO) series are represented in the medicinal chemistry literature is as Markush structures and associated R-group tables. The Markush structure shows a central core or molecular scaffold that is common to the series with R groups that indicate the points of variability that have been explored in the series. The associated R-group table shows the substituent combinations that exist in individual molecules in the series together with properties of those compounds. This format provides an intuitive way of visualising any structure-activity relationship (SAR) that is present. Automated approaches that attempt to reproduce this well understood format, such as the SAR map, are based on maximum common substructure approaches and do not take account of small changes that may be made to the core structure itself or of the situation where more than one core exists in the data. Here we describe an automated approach to represent LO series that is based on reduced graph descriptions of molecules. A publicly available LO dataset from a drug discovery programme at GSK is analysed to show how the method can group together compounds from the same series even when there are small substructural differences within the core of the series while also being able to identify different related compound series. The resulting visualisation is useful in identifying areas where series are under explored and for mapping design ideas onto the current dataset. The code to generate the visualisations is released into the public domain to promote further research in this area.Scientific contribution: We describe a software tool for analysing lead optimisation series using reduced graph representations of molecules. The representation allows compounds that have similar but not identical chemical scaffolds to be grouped together and is, therefore, an advance on methods that are based on the more traditional Markush structure and SAR tables. The software is a useful addition to the med chem toolbox as it can provide a holistic view of lead optimisation data by representing what might otherwise be seen as separate series as a single series of compounds.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12023594 | PMC |
http://dx.doi.org/10.1186/s13321-025-01002-7 | DOI Listing |
ERJ Open Res
September 2025
Department of Bioanalysis, Pharmaceutical Care Unit, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium.
Background: In Belgium, age-standardised hospital admission and mortality rates for asthma and COPD are higher than the European average. Understanding the factors that lead to a hospitalised exacerbation and/or mortality is needed to optimise patient management.
Methods: Patients ≥18 years old obtaining two claims for drugs for obstructive airway diseases (ATC code R03) in 1 year between 2017 and 2022 were identified in Belgian nationwide claims-based data.
BMC Health Serv Res
September 2025
Institute of General Practice, Rostock University Medical Center, Doberaner Str. 142, Rostock, 18057, Germany.
Background: Post-viral syndromes, including long- and post-COVID, often lead to persistent symptoms such as fatigue and dyspnoea, affecting patients' daily lives and ability to work. The COVI-Care M-V trial examines whether interprofessional, patient-centred teleconsultations, initiated by general practitioners in cooperation with specialists, can help reduce symptom burden and improve care for patients.
Methods: To evaluate the effectiveness of the intervention under routine care conditions, a cluster-randomised controlled trial is being conducted.
JPRAS Open
September 2025
Department of Plastic, Reconstructive, & Aesthetic Surgery, Singapore General Hospital, Outram Road, Singapore 169608, Singapore.
Introduction: Burn injuries affecting specialised areas such as the face and hands require durable skin coverage and complete graft "take" to prevent scarring and functional impairment. Failure to achieve these outcomes can lead to long-term complications. This presentation aims to describe an approach of delayed autografting in these regions, following a "trial of allograft" to optimise wound bed preparation.
View Article and Find Full Text PDFBMJ Open
September 2025
Radiotherapy Department, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, England, UK.
Introduction: There are estimated to be 3.4 million patients in the UK living after a diagnosis of cancer. We know very little about their quality of life or healthcare usage.
View Article and Find Full Text PDFArch Microbiol
September 2025
Medical and Biological Computing Laboratory, School of Biosciences and Technology (SBST), Vellore Institute of Technology (VIT), Vellore, 632014, India.
Salmonella enterica serovar Typhi, the etiological agent of Typhoid fever, remains a critical public health concern associated with high morbidity in many developing countries. The widespread emergence of multidrug-resistant (MDR) Salmonella Typhi strains against the fluoroquinolone group of antibiotics, particularly ciprofloxacin, poses a significant global therapeutic challenge with underlying resistance due to mutations in quinolone-resistance determining region (QRDR) of gyrA gene, encoding DNA gyrase subunit A (GyrA). In pursuit of alternative therapeutic candidates, the present study was designed to evaluate ciprofloxacin analogues against prevalent GyrA mutations (S83F, D87G, and D87N) to overcome fluoroquinolone resistance through machine learning (ML)-based approach.
View Article and Find Full Text PDF